前列地尔脂微球载体制剂对AECOPD合并慢性肺源性心脏病肺动脉高压疗效的临床研究

目的评价前列地尔脂微球载体制剂（L ipo PGE1）治疗AECOPD合并慢性肺源性心脏病肺动脉高压患者的疗效。方法 60例AECOPD合并慢性肺源性心脏病肺动脉高压患者随机分为治疗组和对照组,治疗组在常规治疗的基础上加用L ipoPGE1 10μg,对照组仅常规治疗。治疗前后检测肺动脉收缩压（SPAP）、肺动脉平均压（MPAP）、肺动脉舒张压（DPAP）、动脉血氧分压（PaO2）、动脉二氧化碳分压（PaCO2）、肺功能FEV1和FEV1/FVC。结果治疗后SPAP、MPAP、DPAP、PaCO2较治疗前明显降低,PaO2、FEV1和FEV1/FVC较治疗前显著增加,与对照组相比有显著差异（P〈0.05）。结论 PGE1治疗AECOPD合并慢性肺源性心脏病肺动脉高压能降低肺动脉压力,改善动脉血气和肺功能。

Clinical study of lipo-prostaglandin E1 on pulmonary hypertension in patients with AECOPD and chronic pulmonary heart disease

Objective To evaluate the effects of lipo-prostaglandin E1（PGE1） on the AECOPD and chronic pulmonary heart disease with pulmonary hypertension.Methods60 patients of AECOPD and chronic pulmonary heart disease with pulmonary hypertension were randomly divided into therapy group and control group.The patients in therapy group received therapy plus intravenous 10 μg PGE.And the patients in control group received routine therapy.Before and after therapy,systolic pulmonary artery pressure,mean pulmonary artery pressure（MPAP）,pulmonary artery diastolic pressure（DPAP）,arterial partial pressure of oxygen（PaO2）,arterial carbon dioxide tension（PaCO2）,lung function FEV1 and FEV1/FVC were measured.ResultAfter treatment,SPAP,MPAP,DPAP,PaCO2 significantly lower than before treatment,PaO2,FEV1 and FEV1/FVC were significantly increased than that before treatment,compared with the control group were significantly different（P0.05）.ConclusionPGE1 treatment of AECOPD and chronic pulmonary heart disease with pulmonary hypertension reduces pulmonary artery pressure,improve arterial blood gas and pulmonary function.